牛牛AI助理已提取核心訊息
Bristol-Myers Squibb Company, through its subsidiary Rudolph Merger Sub Inc., has announced an amendment to its tender offer to acquire all outstanding shares of RayzeBio, Inc. The offer, priced at $62.50 per share in cash, is detailed in an amended Schedule TO filed with the SEC on February 16, 2024. The amendment provides updated financial information, indicating that Bristol-Myers Squibb estimates a requirement of approximately $4.1 billion to complete the acquisition and related expenses. The company has confirmed the availability of sufficient funds to finance the acquisition, with $11.46 billion in cash and cash equivalents as of December 31, 2023. The funding sources include cash on hand, proceeds from a recent $13 billion Notes Offering, and potential short-term debt arrangements. The Notes Offering, completed on...Show More
Bristol-Myers Squibb Company, through its subsidiary Rudolph Merger Sub Inc., has announced an amendment to its tender offer to acquire all outstanding shares of RayzeBio, Inc. The offer, priced at $62.50 per share in cash, is detailed in an amended Schedule TO filed with the SEC on February 16, 2024. The amendment provides updated financial information, indicating that Bristol-Myers Squibb estimates a requirement of approximately $4.1 billion to complete the acquisition and related expenses. The company has confirmed the availability of sufficient funds to finance the acquisition, with $11.46 billion in cash and cash equivalents as of December 31, 2023. The funding sources include cash on hand, proceeds from a recent $13 billion Notes Offering, and potential short-term debt arrangements. The Notes Offering, completed on February 14, 2024, is not contingent upon the completion of the acquisition but includes mandatory redemption clauses for certain notes if the acquisition of Karuna Therapeutics, Inc. does not occur within a specified timeframe. The tender offer is not subject to any financing condition, and the amendment emphasizes that the financial condition of Bristol-Myers Squibb and its subsidiary is not relevant to shareholders' decisions regarding the tender offer.
百時美施貴寶公司通過其子公司Rudolph Merger Sub Inc. 宣佈對收購RayzeBio, Inc.所有已發行股份的要約進行修訂。該要約定價爲每股現金62.50美元，詳見2024年2月16日向美國證券交易委員會提交的經修訂的附表TO。該修正案提供了最新的財務信息，表明百時美施貴寶估計需要約41億美元才能完成收購和相關費用。該公司已確認有足夠的資金爲收購融資，截至2023年12月31日，現金及現金等價物爲114.6億美元。資金來源包括手頭現金、最近130億美元票據發行的收益以及潛在的短期債務安排。本次票據發行於2024年2月14日完成，不以收購完成爲前提，但如果未在規定的時間範圍內收購Karuna Therapeutics, Inc.，則包括某些票據的強制性贖回條款。本次要約不受任何融資條件的約束，該修正案強調百時美施貴寶及其子公司的財務狀況與股東關於要約的決定無關。
百時美施貴寶公司通過其子公司Rudolph Merger Sub Inc. 宣佈對收購RayzeBio, Inc.所有已發行股份的要約進行修訂。該要約定價爲每股現金62.50美元，詳見2024年2月16日向美國證券交易委員會提交的經修訂的附表TO。該修正案提供了最新的財務信息，表明百時美施貴寶估計需要約41億美元才能完成收購和相關費用。該公司已確認有足夠的資金爲收購融資，截至2023年12月31日，現金及現金等價物爲114.6億美元。資金來源包括手頭現金、最近130億美元票據發行的收益以及潛在的短期債務安排。本次票據發行於2024年2月14日完成，不以收購完成爲前提，但如果未在規定的時間範圍內收購Karuna Therapeutics, Inc.，則包括某些票據的強制性贖回條款。本次要約不受任何融資條件的約束，該修正案強調百時美施貴寶及其子公司的財務狀況與股東關於要約的決定無關。
有用
沒用